ATOM Study 2006.

Study characteristics
Methods	Study design: parallel‐group RCT, with 2‐week run‐in period Study centre: 1 Number randomised: 400 children Study follow‐up: 2 years Exclusions and losses to follow‐up: no exclusions; 54 (13.5%) were lost to follow‐up
Participants	Age: mean = 9.2 years (range 6‐12 years) Gender: 220 boys, 180 girls Culture: Chinese (94%) and Indian children (4%) in Singapore Inclusion criteria:  age 6‐12 years myopia with SER error between −1.00 D and −6.00 D in each eye as measured by cycloplegic autorefraction distance vision correctable to logMAR 0.2 or better in both eyes normal ocular health good general health with no history of cardiac or significant respiratory disease normal binocular function and stereopsis willingness and ability to tolerate monocular cycloplegia and mydriasis Exclusion criteria:  astigmatism > −1.50 D by cycloplegic autorefraction IOP ≥ 21 mmHg allergies to atropine, cyclopentolate, proparacaine, or benzalkonium chloride  previous or current use of contact lenses, BFs, PALs, or other forms of myopia treatment amblyopia or manifest strabismus, including intermittent tropia
Interventions	Atropine (n = 200): 1 eye was randomised to 1 drop of 1% atropine sulfate nightly; the other eye received nothing Placebo control (n = 200): 1 eye was randomised to 1 drop of vehicle nightly; the other eye received nothing Note: all children received single vision photochromatic lenses for correction of refractive errors
Outcomes	Primary efficacy outcome Progression of myopia defined as the change in SER error from baseline and measured by cycloplegic autorefraction Secondary efficacy outcome Change in AL from baseline and measured by A‐scan ultrasonography Primary safety outcome Occurrence of AEs Secondary safety outcomes BCVA, IOP, slit‐lamp biomicroscopy, fundus examination Measurements taken at baseline and annually for 2 years Note: baseline measurements recorded 2 weeks after treatment began to allow for stabilisation of the cycloplegic effect of atropine Unit of analysis: only 1 eye per child randomised to receive treatment (fellow eyes were controls)
Notes	Study dates: enrolment between April 1999 and September 2000 Trial registration: not reported Materials: vehicle drops were prepared by Alcon Laboratories; spectacles were SOLA Transitions SVLs Funding source: National Medical Research Council, Singapore Additional data: study author provided unpublished data via email correspondence